The group’s principal activities include research and development of a novel drug and drug targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor associated protein. In May 2006, the group acquired Raptor Pharmaceutical Inc. The group operates from the United States.
